WSTAM
CRVO icon

Wilbanks Smith & Thomas Asset Management’s CervoMed CRVO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-585
Closed -$22K – 512
2021
Q3 		$22K Hold
585
– – ﹤0.01% 503
2021
Q2 		$32K Hold
585
– – ﹤0.01% 491
2021
Q1 		$40K Buy
+585
New +$49.1K ﹤0.01% 467

Other funds holding CRVO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CRVO Position: Q4 2021 in Review

Wilbanks Smith & Thomas Asset Management sold out of CervoMed (CRVO) in Q4 2021, closing a stake of 585 shares — an estimated $22K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CRVO in Q1 2021 and held it in 3 quarters. The position peaked at $40K in Q1 2021. 20 funds tracked by Wall St. Rank hold CRVO as of Q4 2021.

  • Wilbanks Smith & Thomas Asset Management reported no remaining CervoMed position as of Q4 2021 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 585 CervoMed shares in Q4 2021, an estimated $22K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in CervoMed in Q1 2021 and held it in 3 quarters.
  • Wilbanks Smith & Thomas Asset Management's CervoMed position peaked at $40K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held CervoMed as of Q4 2021.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2021, filed 8 Feb 2022.